Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Financing Activities: 2015-2025

Historic Cash from Financing Activities for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $17.2 million.

  • Editas Medicine's Cash from Financing Activities was N/A to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.7 million, marking a year-over-year change of. This contributed to the annual value of $56.0 million for FY2024, which is 52.54% down from last year.
  • Per Editas Medicine's latest filing, its Cash from Financing Activities stood at $17.2 million for Q3 2025, which was up 131.64% from $7.4 million recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Cash from Financing Activities peaked at $261.5 million during Q1 2021, and registered a low of -$1.4 million during Q1 2025.
  • Its 3-year average for Cash from Financing Activities is $24.7 million, with a median of $4.0 million in 2023.
  • In the last 5 years, Editas Medicine's Cash from Financing Activities soared by 31,923.16% in 2023 and then slumped by 848.44% in 2025.
  • Editas Medicine's Cash from Financing Activities (Quarterly) stood at $1.1 million in 2021, then plummeted by 41.44% to $619,000 in 2022, then dropped by 16.96% to $514,000 in 2023, then spiked by 10,700.19% to $55.5 million in 2024, then spiked by 2,201.86% to $17.2 million in 2025.
  • Its last three reported values are $17.2 million in Q3 2025, $7.4 million for Q2 2025, and -$1.4 million during Q1 2025.